Medifast, Inc.

NYSE:MED 주식 보고서

시가총액: US$219.9m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Medifast 관리

관리 기준 확인 3/4

Medifast's CEO는 Dan Chard, Oct2016 에 임명되었습니다 의 임기는 7.67 년입니다. 총 연간 보상은 $ 7.04M, 14.2% 로 구성됩니다. 14.2% 급여 및 85.8% 보너스(회사 주식 및 옵션 포함). 는 $ 3.05M 가치에 해당하는 회사 주식의 1.46% 직접 소유합니다. 3.05M. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 7.7 년입니다.

주요 정보

Dan Chard

최고 경영자

US$7.0m

총 보상

CEO 급여 비율14.2%
CEO 임기7.7yrs
CEO 소유권1.5%
경영진 평균 재임 기간4.3yrs
이사회 평균 재임 기간7.7yrs

최근 관리 업데이트

Recent updates

Medifast: Significant Undervaluation Even As Struggles Persist

May 24

At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

May 24
At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

May 24
Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

May 06
Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

May 01
The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

Medifast: Cheap Valuation, Uncertain Future

Mar 20

Medifast Is Getting Attractive

Mar 07

Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Feb 22
Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Medifast Share Price Loses Weight, But Is There Still Value To Be Had?

Jan 20

Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Dec 09
Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome

Nov 24

Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Nov 21
Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Medifast: Unveiling A Challenge Beyond Weight Loss Drugs

Nov 09

Medifast: The Race To Weight-Loss Drugs Not Lost Yet

Oct 09

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Aug 04

Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

Jul 26
Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Jul 21

Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Jul 05
Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast: In Survival Mode Against Diet Pills And The Recession

Jun 14

Medifast Holds Value During Headwinds

May 28

Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M

Feb 21

Medifast: A Low Earnings Multiple Despite Strong Financial Performance

Feb 07

At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Jan 19
At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Medifast declares $1.64 dividend

Dec 08

A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Dec 01
A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 10
Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems

One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates

Nov 08
One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates

Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy

Nov 06

What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Oct 20
What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt

Sep 18
We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt

Medifast declares $1.64 dividend

Sep 08

Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?

Sep 02
Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?

Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good

Aug 21

Medifast, Inc. (NYSE:MED) Analysts Are Reducing Their Forecasts For This Year

Aug 09
Medifast, Inc. (NYSE:MED) Analysts Are Reducing Their Forecasts For This Year

Are Medifast, Inc. (NYSE:MED) Investors Paying Above The Intrinsic Value?

Jul 27
Are Medifast, Inc. (NYSE:MED) Investors Paying Above The Intrinsic Value?

What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Jul 12
What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Medifast And Its Real Value

Jun 24

Medifast: Growth And Value At A Reasonable Price

May 17

CEO 보상 분석

Dan Chard 의 보수는 Medifast 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

US$68m

Dec 31 2023US$7mUS$1m

US$99m

Sep 30 2023n/an/a

US$120m

Jun 30 2023n/an/a

US$133m

Mar 31 2023n/an/a

US$142m

Dec 31 2022US$6mUS$981k

US$144m

Sep 30 2022n/an/a

US$151m

Jun 30 2022n/an/a

US$157m

Mar 31 2022n/an/a

US$165m

Dec 31 2021US$7mUS$914k

US$164m

Sep 30 2021n/an/a

US$158m

Jun 30 2021n/an/a

US$150m

Mar 31 2021n/an/a

US$125m

Dec 31 2020US$6mUS$909k

US$103m

Sep 30 2020n/an/a

US$95m

Jun 30 2020n/an/a

US$76m

Mar 31 2020n/an/a

US$76m

Dec 31 2019US$5mUS$843k

US$78m

Sep 30 2019n/an/a

US$74m

Jun 30 2019n/an/a

US$72m

Mar 31 2019n/an/a

US$64m

Dec 31 2018US$2mUS$675k

US$56m

Sep 30 2018n/an/a

US$47m

Jun 30 2018n/an/a

US$40m

Mar 31 2018n/an/a

US$34m

Dec 31 2017US$2mUS$650k

US$28m

보상 대 시장: Dan 의 총 보상 ($USD 7.04M )은 US 시장( $USD 1.62M ).

보상과 수익: Dan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Dan Chard (59 yo)

7.7yrs

테뉴어

US$7,039,062

보상

Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December...

리더십 팀

이름위치테뉴어보상소유권
Daniel Chard
Executive Chairman & CEO7.7yrsUS$7.04m1.46%
$ 3.2m
James Maloney
Chief Financial Officer3.9yrsUS$2.01m0.091%
$ 200.5k
Anthony Tyree
Chief Business Operations Officer2.4yrsUS$1.61m0.12%
$ 256.4k
Jason Groves
Executive VP12.6yrsUS$1.63m0.12%
$ 255.3k
Nicholas Johnson
Chief Field Operations Officer5.3yrsUS$1.70m0.095%
$ 208.8k
Jonathan MacKenzie
VP of Finance & Chief Accounting Officer2.8yrs데이터 없음0.0050%
$ 10.9k
Steven Zenker
Vice President of Investor Relations1.3yrs데이터 없음데이터 없음
Claudia Greninger
Chief Human Resources Officer4.7yrs데이터 없음데이터 없음

4.3yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: MED 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Daniel Chard
Executive Chairman & CEO7.7yrsUS$7.04m1.46%
$ 3.2m
Jeffrey Brown
Lead Independent Director9yrsUS$263.42k0.054%
$ 118.9k
George Bray
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Michael Hoer
Independent Director6yrsUS$249.72k0.017%
$ 36.6k
Andrea Thomas
Independent Director5yrsUS$249.72k0.058%
$ 128.6k
John Foreyt
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Ming Xian
Independent Director6yrsUS$219.61k데이터 없음
Lawrence Cheskin
Chairman of Scientific Advisory Board15.6yrs데이터 없음데이터 없음
Sylvia Rowe
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Scott Schlackman
Independent Director9yrsUS$252.44k0.099%
$ 216.7k
John Hayes
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Mark Messina
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

7.7yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: MED 의 이사회는 경험(평균 재직 기간 7.7 년)으로 간주됩니다.